Malignant mixed epithelial and mesenchymal tumor of corpus uteri

Malignant mixed epithelial and mesenchymal tumor of the corpus uteri, also known as malignant mixed Müllerian tumor (MMMT) or uterine carcinosarcoma, is a rare and aggressive neoplasm arising in the body of the uterus. This tumor is characterized by the presence of both malignant epithelial (carcinomatous) and malignant mesenchymal (sarcomatous) components within the same mass. The carcinomatous component may include endometrioid, serous, or clear cell patterns, while the sarcomatous component can be homologous (resembling normal uterine tissues such as endometrial stroma or smooth muscle) or heterologous (containing elements foreign to the uterus such as cartilage, bone, or skeletal muscle). The disease primarily affects the female reproductive system, specifically the uterine corpus, and can spread to the pelvic and abdominal organs, lymph nodes, and distant sites. Patients typically present with abnormal or postmenopausal vaginal bleeding, pelvic pain, and a rapidly enlarging uterus. A mass may protrude through the cervical os. The disease predominantly affects postmenopausal women, with a median age of diagnosis in the sixth to seventh decade of life. Risk factors may include prior pelvic radiation, obesity, and exogenous estrogen use. Diagnosis is established through histopathological examination of tissue obtained by biopsy or hysterectomy. Treatment generally involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, often accompanied by pelvic and para-aortic lymph node dissection for surgical staging. Adjuvant therapy may include chemotherapy (commonly platinum-based regimens combined with ifosfamide or paclitaxel) and/or radiation therapy, depending on the stage and extent of disease. Despite multimodal treatment, the prognosis remains poor, with high rates of recurrence and metastasis. Ongoing clinical trials continue to explore novel therapeutic approaches, including targeted therapies and immunotherapy, to improve outcomes for patients with this challenging malignancy.

Common questions about Malignant mixed epithelial and mesenchymal tumor of corpus uteri